Roxana Dronca, MD
Expression of the apoptosis regulator protein BIM could help predict response to PD-1 blockade in patients with melanoma, according to a study presented at the AACR International Cancer Immunotherapy Conference.
A major advantage of the method used is the use of circulating peripheral blood cells, which will avoid repeated tissue biopsies for the patient.
FDA Scrutinizes Pathway Genomics' Direct-to-Consumer Genetic Test
The direct-to-consumer (DTC) screening test CancerIntercept Detect has not undergone proper regulatory clearance as a “device” and could therefore harm public health, according to a letter issued by the FDA to the manufacturer of the test, Pathway Genomics.
According to the company's website, CancerIntercept Detect has been developed for individuals who are at risk for known hereditary cancer, have a family history of cancer, whose lifestyle choices may increase their risk for cancer, or who may have had environmental exposure to cancer causing agents. The company claims to have a College of American Pathologists and Clinical Laboratory Improvement Amendments accreditation.
Working Group Announces Precision Medicine Initiative Blueprint
The Precision Medicine Initiative (PMI) Working Group has created an action plan that could help propel President Obama’s vision to better integrate personalized medicine in healthcare, Francis Collins, MD, PhD, announced in a conference call.
... to read the full story